新江湖 | 金夷、林正伟、陈守登、郭霆加入BiG！

BiG生物创新社

2024-10-13

集结大分子药物和细胞基因疗法的领军人物和中坚力量，集行业之声，让中国医药界听到 BiG 的声音，让世界听中国说。BiG 持续坚持非营利机制；坚持“会员所有、会员自治、服务会员“（Of member, by member, for member）的治理原则。七载春秋，从成立之初的21人，日渐壮大已成长近500余位个人会员、39家企业会员的生物医药创新社群。

2021年8月，BiG迎来生物医药领域4位个人新会员！携手同行，共建Biologics闭环新江湖！

No.1 金夷

CSO

吉凯医药

单位类型： Biotech/pharma
个人简介： Dr. Yi Jin obtained her Ph.D. degree from Iowa State University and received postdoc training at University of California at Berkeley later. She has 16 years‘ experience on therapeutic biologics discovery and development in Pharmaceutical and Biotech companies in US and China. Worked as project team leaders at Bayer (USA), responsible for establishing and developing antibody discovery and novel technology platforms. During her tenure, she led multiple projects through different stages of the development, including target discovery and validation on autoimmune disease and cancer immunotherapy. She also took senior R&D positions at Second Genome (US), Chempartner (US) and GenScript (US and China). Currently, she serves as Chief Scientific Officers in Shanghai Genbase Biotechnology Co., Ltd.

推荐人： 卢宏韬、袁纪军

No.2 林正伟

BD Director

创胜集团

单位类型： Biotech/pharma
个人简介： Zhengwei has held different roles in life sciences industry with experiences in technology licensing, business development, venture investment, M&A, and market access. Prior to joining Transcenta, he was a Technology Licensing Manager at City of Hope National Medical Center, where he managed licensing deals and contract negotiation in areas including oncology and metabolic diseases. Before City of Hope, he worked as a life sciences venture capitalist at Fortune Capital where he built and managed portfolios in various verticals including therapeutics, vaccine, genetic diagnosis, and bioprocessing. Zhengwei started his career at Youcare Pharma Group, where he executed an M&A deal with Allergan and initiated co-development deals with local biotech post-closing. Zhengwei holds a Ph.D. in Cancer Cell Biology from the Peking Union Medical College and an MBA from the USC Marshall School of Business.

推荐人： 钱雪明、肖志华

No.3 陈守登

研究员

中山大学附属第五医院

单位类型： 医院临床机构

个人简介： 入选广东省高层次人才计划（ZJRC），广东省“优粤卡”人才计划，珠海市英才计划。长期从事病毒蛋白，组蛋白与病毒类组蛋白翻译后修饰机制研究，同时结合临床资源从事病毒类抗体药物研发及体外诊断试剂研发工作。目前在新型冠状病毒SARS-CoV-2中开展研究及转化工作，包括SARS-CoV-2 N蛋白参与机体补体系统异常激活的结构与功能研究、N蛋白特异性抗体在新冠病毒肺炎中的应用、新冠病毒蛋白影响免疫细胞的功能研究等。

推荐人： 刘迎芳、许英达

No.4 郭霆

Managing Partner, Portfolio Manager 超弦基金
单位类型： 投资机构
个人简介： Dr. Ting Guo is the Founder and Portfolio Manager of Superstring Capital, a healthcare-dedicated fund focused on public and private investments in pharmaceutical/biotech, medtech and healthcare services across both China and the US.
Prior to founding Superstring, Ting was a Partner at Teng Yue Partners, a multi-billion New York-based fund specializing in equity investments in China. At Teng Yue, Ting led the firm’s healthcare research for both public and private investments. Ting joined Teng Yue in 2015 as the firm’s first healthcare and expanded Teng Yue’s healthcare portfolio to become one of the largest sector exposures of the fund. Ting also led and structured the firm’s first private investments in the healthcare sector, including serving as a board member for several of the companies.
Prior to Teng Yue, Ting was a management consultant at McKinsey & Company, where he advised senior management of leading global pharmaceutical, biotech, medtech and healthcare services companies on a wide range of strategic issues. As a key member of McKinsey’s private equity practice, Ting also advised financial sponsors on strategic transactions within the healthcare sector.
Ting obtained his PhD in Neuroscience from Johns Hopkins School of Medicine, under the advice of Dr. David Ginty (currently the Edward Lefler Professor of Neuroscience of Harvard Medical School, a member of US National Academy of Sciences, and a member of Howard Hughes Medical Institute). He obtained his Bachelor of Science in Biological Sciences from Tsinghua University, where he graduated at the top of his class.

推荐人： 杨颖、李文宝

近

期

回

顾

上下滑动查看更多内容